PCSK9 and atherosclerosis: Recent results from trials with long follow-up on PCSK9 inhibitors (iPCSK9) in patients with ASCVD have shown a significant 15% relative risk reduction for major cardiovascular events, especially in patients with recent or progressive CHD or with involvement of several vascular territories [27,28].